drugset / Trial / NCT05387785
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to assess safety and tolerability of once daily (QD) and twice daily (BID) dosing of ANG-3070 in subjects with idiopathic pulmonary fibrosis (IPF) who are treatment-naïve, refused therapy, or discontinued for any reason current standard of care with nintedanib or pirfenidone.
Timeline
- Start
- 2022-06
- Primary completion
- 2022-11
- Completion
- 2022-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANG-3070 | Unknown | 300 mg | Oral |
| Subject | ANG-3070 | Unknown | 500 mg | Oral |